
InnoCare Secures Approval for ICP-248 AML Clinical Trial in China
InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company specializing in cancer and autoimmune disease treatments, has received approval to conduct a clinical trial for its BCL2 inhibitor, ICP-248,…











